AU2019223187B2 - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents

Dosage forms and methods for enantiomerically enriched or pure bupropion Download PDF

Info

Publication number
AU2019223187B2
AU2019223187B2 AU2019223187A AU2019223187A AU2019223187B2 AU 2019223187 B2 AU2019223187 B2 AU 2019223187B2 AU 2019223187 A AU2019223187 A AU 2019223187A AU 2019223187 A AU2019223187 A AU 2019223187A AU 2019223187 B2 AU2019223187 B2 AU 2019223187B2
Authority
AU
Australia
Prior art keywords
bupropion
dosage form
dextromethorphan
fold
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019223187A
Other languages
English (en)
Other versions
AU2019223187A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of AU2019223187A1 publication Critical patent/AU2019223187A1/en
Priority to AU2022204521A priority Critical patent/AU2022204521B2/en
Application granted granted Critical
Publication of AU2019223187B2 publication Critical patent/AU2019223187B2/en
Priority to AU2024205858A priority patent/AU2024205858A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019223187A 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion Active AU2019223187B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022204521A AU2022204521B2 (en) 2018-02-23 2022-06-27 Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2024205858A AU2024205858A1 (en) 2018-02-23 2024-08-17 Dosage forms and methods for enantiomerically enriched or pure bupropion

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US62/634,718 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US62/794,469 2019-01-18
US201962809480P 2019-02-22 2019-02-22
US62/809,480 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204521A Division AU2022204521B2 (en) 2018-02-23 2022-06-27 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (2)

Publication Number Publication Date
AU2019223187A1 AU2019223187A1 (en) 2020-09-17
AU2019223187B2 true AU2019223187B2 (en) 2022-07-28

Family

ID=67688503

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019223187A Active AU2019223187B2 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2022204521A Active AU2022204521B2 (en) 2018-02-23 2022-06-27 Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2024205858A Pending AU2024205858A1 (en) 2018-02-23 2024-08-17 Dosage forms and methods for enantiomerically enriched or pure bupropion

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022204521A Active AU2022204521B2 (en) 2018-02-23 2022-06-27 Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2024205858A Pending AU2024205858A1 (en) 2018-02-23 2024-08-17 Dosage forms and methods for enantiomerically enriched or pure bupropion

Country Status (19)

Country Link
EP (1) EP3755312A4 (https=)
JP (3) JP2021513998A (https=)
KR (3) KR20230075531A (https=)
CN (2) CN112087999A (https=)
AU (3) AU2019223187B2 (https=)
BR (1) BR112020017179A2 (https=)
CA (1) CA3092076A1 (https=)
CL (1) CL2020002166A1 (https=)
CR (1) CR20200415A (https=)
EC (1) ECSP20060179A (https=)
IL (2) IL276871B2 (https=)
MA (1) MA51914A (https=)
MX (2) MX2020008704A (https=)
MY (1) MY202993A (https=)
NI (1) NI202000056A (https=)
NZ (1) NZ767378A (https=)
PE (1) PE20211752A1 (https=)
SG (1) SG11202008056SA (https=)
WO (1) WO2019165379A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
KR20220066930A (ko) * 2019-09-20 2022-05-24 액섬 테라퓨틱스, 인크. 에난티오머적으로 풍부한 또는 순수한 부프로피온을 위한 제형 및 방법
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
US20170304230A1 (en) * 2013-11-05 2017-10-26 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
ME00391B (me) * 2003-08-08 2011-10-10 Biovail Laboratories Int Srl Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20170304230A1 (en) * 2013-11-05 2017-10-26 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion

Also Published As

Publication number Publication date
MX2023009281A (es) 2023-08-17
CR20200415A (es) 2021-02-03
NZ767378A (en) 2024-03-22
JP2021513998A (ja) 2021-06-03
WO2019165379A1 (en) 2019-08-29
KR20230075531A (ko) 2023-05-31
KR20240091043A (ko) 2024-06-21
ECSP20060179A (es) 2020-12-31
MA51914A (fr) 2020-12-30
NI202000056A (es) 2021-01-11
IL276871A (en) 2020-10-29
AU2022204521A1 (en) 2022-07-21
EP3755312A1 (en) 2020-12-30
EP3755312A4 (en) 2022-03-16
CA3092076A1 (en) 2019-08-29
CL2020002166A1 (es) 2020-10-23
AU2019223187A1 (en) 2020-09-17
BR112020017179A2 (pt) 2020-12-22
JP2024075655A (ja) 2024-06-04
MX2020008704A (es) 2020-12-07
IL276871B2 (en) 2024-11-01
AU2022204521B2 (en) 2024-09-05
MY202993A (en) 2024-05-31
IL313368A (en) 2024-08-01
JP2022153638A (ja) 2022-10-12
CN112087999A (zh) 2020-12-15
PE20211752A1 (es) 2021-09-06
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
CN120827545A (zh) 2025-10-24
KR20210003091A (ko) 2021-01-11
AU2024205858A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
AU2022204521B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20210196704A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20210177834A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US10695304B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216801A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216800A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11179352B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20200222339A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2024200081A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20220249405A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20260014142A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20240277635A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)